Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Common Equity (2016 - 2025)

Apyx Medical (APYX) has disclosed Common Equity for 16 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 1.43% year-over-year to $14.5 million, compared with a TTM value of $14.5 million through Dec 2025, up 1.43%, and an annual FY2025 reading of $14.5 million, up 1.43% over the prior year.
  • Common Equity was $14.5 million for Q4 2025 at Apyx Medical, up from $6.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $60.2 million in Q1 2021 and bottomed at $6.1 million in Q3 2025.
  • Average Common Equity over 5 years is $31.8 million, with a median of $34.9 million recorded in 2023.
  • The sharpest move saw Common Equity plummeted 66.66% in 2024, then rose 1.43% in 2025.
  • Year by year, Common Equity stood at $54.0 million in 2021, then plummeted by 30.02% to $37.8 million in 2022, then dropped by 28.76% to $26.9 million in 2023, then tumbled by 46.75% to $14.3 million in 2024, then rose by 1.43% to $14.5 million in 2025.
  • Business Quant data shows Common Equity for APYX at $14.5 million in Q4 2025, $6.1 million in Q3 2025, and $7.5 million in Q2 2025.